Coenzyme-A Inc. (PPII) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 1.59: the stock has moved about 59% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerCoenzyme-A Inc. (PPII) trades at $0.0002. Coenzyme-A Inc. formulates and manufactures nutraceutical supplements, skin, and hair care products, operating both domestically and internationally. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for PPII: PPII does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Coenzyme-A Inc. (PPII) Healthcare & Pipeline Overview
Coenzyme-A Inc. is a nutraceutical and personal care product manufacturer, offering a range of supplements, skin, and hair care solutions. Founded in 1998, the company targets diverse consumer needs with specialized formulas for energy, beauty, and wellness, operating in the competitive specialty and generic drug market.
What Is the Investment Thesis for PPII?
Coenzyme-A Inc. presents a focused approach to the nutraceutical and personal care market, with a diverse product range and international presence. The company's gross margin of 66.1% indicates efficient operations. Key value drivers include expanding its product lines and penetrating new geographic markets. Growth catalysts involve capitalizing on the increasing consumer interest in health and wellness products. Potential risks include competition from larger players and the challenges of operating in the OTC market. Investors may want to evaluate the company's OTC status and associated risks.
Based on FMP financials and quantitative analysis
PPII Key Highlights
Coenzyme-A Inc. operates in the nutraceutical and personal care market, offering a range of supplements and skin/hair care products.
- The company's gross margin stands at 66.1%, reflecting its operational efficiency.
- Coenzyme-A Inc. was founded in 1998 and is based in Lynnwood, Washington.
- The company's beta is 1.59, indicating higher volatility compared to the market average.
- Coenzyme-A Inc. does not offer a dividend, reinvesting earnings for growth.
Who Are PPII's Competitors?
PPII is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AKAN Akanda Corp. | $1.98 | -10.41% | — | |
| SNOA Sonoma Pharmaceuticals, Inc. | $1.24 | -0.80% | $5.94M | — |
| BFRI Biofrontera Inc. | $1.01 | -2.40% | $13.0M | — |
| COSM COSM | $0.38 | -1.58% | $20.7M | — |
| QNTM Quantum BioPharma Ltd. | $3.44 | +0.44% | $22.0M | — |
| AYTU Aytu BioPharma, Inc. | $2.07 | -0.96% | $22.2M | — |
| TXMD TherapeuticsMD, Inc. | $2.05 | +0.99% | $23.7M | — |
| CPHI CPHI | $0.66 | +0.61% | $26.6M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PPII's Key Strengths?
Diverse product portfolio in nutraceuticals and personal care.
- Established presence in the United States and international markets.
- High gross margin of 66.1%.
- Specialized product lines targeting specific health needs.
What Are PPII's Weaknesses?
OTC market listing increases volatility and risk.
- Limited brand recognition compared to larger competitors.
- Dependence on specific distribution channels.
- Potential challenges in navigating regulatory requirements.
What Are the Key Risks for PPII?
Intense competition from established players in the nutraceutical market.
- Changing consumer preferences and trends.
- Regulatory changes and compliance requirements.
- Economic downturns affecting consumer spending on discretionary products.
- Risks associated with operating in the OTC market, including limited liquidity and disclosure.
What Are PPII's Competitive Advantages?
- Proprietary Formulations: Coenzyme-A Inc. may have unique formulations that differentiate its products from competitors.
- Brand Recognition: Established brand recognition in specific product categories can create customer loyalty.
- Distribution Network: A well-established distribution network can provide a competitive advantage.
- Specialized Product Lines: Focus on specific customer segments (e.g., sports nutrition, women's health) can create a niche advantage.
What Does PPII Do?
Coenzyme-A Inc., established in 1998 and headquartered in Lynnwood, Washington, formulates and manufactures a diverse range of nutraceutical supplements, as well as skin and hair care products. The company operates both in the United States and internationally, catering to a broad consumer base with varied health and wellness needs. Its product portfolio includes energy drinks, skin rejuvenating serums, fat management solutions, skin treatments, and products designed to support fatty acid and cholesterol metabolism. Coenzyme-A Inc. also offers nutritional formulas targeting specific health areas, such as bone, joint, ligament, cartilage, and connective tissue support. Furthermore, the company provides specialized product lines tailored to different demographics, including sports-specific formulas, women's health products, and men's health supplements. Its offerings extend to wellness, energy, and body sculpting products, reflecting a comprehensive approach to health and personal care. The company aims to address a wide array of consumer demands within the nutraceutical and personal care markets.
What Products and Services Does PPII Offer?
- Formulates and manufactures nutraceutical supplements.
- Produces skin and hair care products.
- Offers energy drinks and skin rejuvenating serums.
- Develops fat management and skin treatment solutions.
- Creates products for fatty acid and cholesterol metabolism.
- Provides nutritional formulas for bone, joint, and connective tissue support.
- Offers sports-specific, women's, and men's formulas.
- Provides wellness, energy, and body sculpting products.
How Does PPII Make Money?
- Develops and manufactures a range of nutraceutical supplements and personal care products.
- Sells products through various distribution channels, including online retail and partnerships.
- Generates revenue through direct sales to consumers and wholesale distribution.
- Focuses on product innovation and marketing to drive sales and market share.
What Industry Does PPII Operate In?
Coenzyme-A Inc. operates within the specialty and generic drug manufacturing industry, a segment characterized by intense competition and evolving consumer preferences. The global nutraceuticals market is experiencing substantial growth, driven by increasing health awareness and an aging population. Key trends include the rising demand for personalized nutrition and the growing popularity of natural and organic products. Coenzyme-A Inc. competes with established players and emerging brands, requiring continuous innovation and effective marketing strategies to maintain its market position.
Who Are PPII's Key Customers?
- Individuals seeking general health and wellness supplements.
- Consumers looking for skin and hair care solutions.
- Athletes and fitness enthusiasts seeking sports-specific formulas.
- Individuals with specific health concerns, such as joint pain or metabolic issues.
- Retailers and distributors of nutraceutical and personal care products.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Coenzyme-A Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Lynnwood, US. The company is led by CEO Nickoloaus D. Skouras. PPII has traded publicly since 2009.
PPII Financials
PPII Latest News
No recent news available for PPII.
PPII Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for PPII.
Price Targets
Wall Street price target analysis for PPII.
PPII MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for PPII; grades run from A+ (80-100) to F (below 30).
Leadership: Nickoloaus D. Skouras
CEO
Nickoloaus D. Skouras is the CEO of Coenzyme-A Inc. Further research would be needed to provide a comprehensive background on Mr. Skouras's professional experience and credentials. His leadership is pivotal in guiding the company's strategic direction and operational execution.
Track Record: Information regarding Nickoloaus D. Skouras's specific achievements, strategic decisions, and company milestones under his leadership is not available in the provided data. Further research would be needed to assess his track record and contributions to Coenzyme-A Inc.'s performance and growth.
PPII OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Coenzyme-A Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited information available to investors, and trading activity can be sporadic. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation. These companies are not required to adhere to the same stringent reporting standards as those listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited Disclosure: Lack of financial transparency and reporting requirements.
- Low Liquidity: Difficulty in buying or selling shares due to low trading volume.
- Price Volatility: Significant price swings due to limited trading activity.
- Potential for Fraud: Higher risk of fraudulent activities and manipulation.
- Regulatory Scrutiny: Increased regulatory scrutiny and potential for delisting.
- Verify the company's registration and legal standing.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with OTC trading.
- Consult with a qualified financial advisor.
- Check for any regulatory actions or legal disputes.
- Consistent revenue generation from core business activities.
- Clear and transparent communication with investors.
- Independent audits of financial statements (if available).
- Experienced management team with relevant industry expertise.
- Positive customer reviews and testimonials.
PPII Healthcare Stock FAQ
What are the main risks for PPII?
The main risks for Coenzyme-A Inc. include intense competition in the nutraceutical and personal care markets, changing consumer preferences, and regulatory compliance requirements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on available data and may be limited due to the company's OTC listing.